Mark Cunningham
Mark graduated from the University of Hertfordshire and started his career in recombinant protein expression & purification at start-up and biotech companies in England. In 1994, Mark moved to the United States where he contributed towards therapeutic monoclonal antibody development for the Janssen R&D arm of Johnson & Johnson. After a 20-year career with J&J as a scientific and operational leader, Mark moved back to the UK where he has recently joined the UKRI’s Nucleic Acid Therapy Accelerator (NATA) as Head of Operations.
Job Title
Head of Operations
Research Areas
Personal Website